Skip to main content
CBLL logo

CBLL · Ceribell, Inc.

Track CBLL — free
$23.73 +0.36 (+1.54%) At close · Aug 28
Market Cap
$910.71M
Shares
38.38M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-08-10 Ceribell Reports Second Quarter 2026 Financial Results

SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the second quarter ended June 30,

2026-08-10 Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review

Neurology Review Software Enhancements Included as Part of Industry-Leading Ceribell Point-of-Care Brain Monitoring System SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the

2026-08-03 Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform SUNNYVALE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the

2026-07-29 Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe

Medtech Market-Builder Thomas West and Health System Operator Sharon O’Keefe Join Ceribell as Point-of-Care Brain Monitoring Advances Toward Standard of Care SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on

2026-07-28 Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference

SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a

2026-07-20 Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026

SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second

2026-06-08 Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes

Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the Ceribell System as a clinical decision-making tool SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- CeriBell,

2026-05-20 Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference

SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present

2026-05-11 Ceribell Reports First Quarter 2026 Financial Results

SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the first quarter ended March 31,

2026-04-29 Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference

SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott

2026-04-20 Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026

SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first

2026-02-24 Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results

SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year

2026-02-18 Ceribell to Participate in Upcoming March Investor Conferences

SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming

2026-02-10 Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth

2026-01-05 Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution

Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the hospital setting SUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc.

2025-12-30 Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will

Past events

Date Event Type
2026-08-12 Canaccord Genuity 46th Annual Growth Conference Conference
2026-08-10 Ceribell Q2 2026 Earnings Call Earnings call
2026-06-03 William Blair 46th Annual Growth Stock Conference Conference
2026-05-13 Bank of America Securities 2026 Health Care Conference Conference
2026-05-11 Ceribell Q1 2026 Earnings Call Earnings call
2026-03-03 TD Cowen 46th Annual Health Care Conference Conference
2026-03-02 Raymond James 47th Annual Institutional Investors Conference Conference
2026-02-24 Ceribell Q4 2025 Earnings Call Earnings call
2026-01-12 44th Annual J.P. Morgan Healthcare Conference Conference
2025-12-03 Piper Sandler 37th Annual Healthcare Conference Conference
2025-11-20 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Event
2025-11-04 Ceribell Q3 2025 Earnings Call Earnings call
2025-08-12 Canaccord Genuity 45th Annual Growth Conference Conference
2025-08-05 Ceribell Q2 2025 Earnings Call Earnings call
2025-06-03 William Blair 45th Annual Growth Stock Conference Conference
2025-05-14 Bank of America Securities 2025 Health Care Conference Conference
2025-05-08 Ceribell Q1 2025 Earnings Call Earnings call
2025-03-03 45th Annual TD Cowen Health Care Conference Conference
2025-02-25 Ceribell Q4 2024 Earnings Call Earnings call
2025-01-13 43rd Annual J.P. Morgan Healthcare Conference Conference
2024-11-21 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Event
2024-11-12 Ceribell Q3 2024 Earnings Call Earnings call

Source: https://investors.ceribell.com/

Key facts CIK 1861107 CUSIP 15678C102 13F (30d) 106 filings 104 filers Visit website Investor relations